focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAMP.L Regulatory News (AMP)

  • There is currently no data for AMP

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Motif BioSciences

2 Mar 2006 09:12

Amphion Innovations PLC02 March 2006 Amphion Innovations PLC Partner Company Motif BioSciences Announces Completion of $1.875 Million Financing and Commencement of Arabian Gulf Sampling Program 02 March 2006 - Amphion Innovations plc's (Amphion) partner company MotifBioSciences (Motif), a population genetics company focused on the discovery ofgenes causing common diseases by utilising human genetic data from the Persian/Arabian Gulf region, announces that it has completed a $1.875 million financing,and has received and begun analysing the first sets of human genetic samplesfrom the Arabian Gulf. Amphion, the lead investor in this round, previously announced its $500,000investment on 3 January 2006, and holds a 47.22% stake in the Company. Thefinancing, which was oversubscribed, has since completed with a combination ofnew and existing investors. The additional investment will support Motif'ssample collection and sample analysis programs in the Persian/Arabian Gulf, aprogram now well underway with the recent acquisition and analysis of two setsof genetic data from the region. To support the Company's growing research and collaborative efforts, Motif hashired Kevin Arnold, formerly the Executive Director of Operations of GenaissancePharmaceuticals, to serve as Executive Director of Genomic Operations at Motif.Manish Pungliya, formerly Bioinformatics Scientist at GenaissancePharmaceuticals, has been hired to lead Motif's bioinformatics effort. Richard C.E. Morgan, CEO of Amphion and Chairman of the Board of Motif, said: "We are delighted to be moving forward with our programmes in the Gulf. Motifpromises to bring understanding of the genetic component of a variety of medicalafflictions in the region, ranging from rare disorders to ones, like diabetes,that are of interest to people around the world. This understanding can lead tobetter diagnosis and, hopefully, innovative therapeutic strategies to help thoseafflicted in the region and elsewhere." Stephen Cass, Chief Executive Officer of Motif, said: "The strong support of our existing investors, as well as the addition ofimportant new investors from the Gulf, is a great show of confidence in Motif'sstrong progress. In a region which we think holds perhaps the most promisingsources of future genetic disease discoveries, this latest round will enable usto aggressively pursue our research and work plan in the region. Given ourcurrent progress in acquiring samples, raising capital, and developingpartnerships with key Gulf healthcare organizations, we believe that 2006 can bea year of rapid growth for the Company's research program, pharma industryinterest, and shareholder value." For More Information: Financial DynamicsBen Atwell / John Gilbert +44 (0) 20 7831 3113 Amphion InnovationsRichard Morgan, CEO 1 (212) 210-6224Ben Austin, Investor Relations 1 (212) 210-6248baustin@amphionplc.com 1 (917) 686-3979 mobile About Amphion Innovations plc Amphion Innovations plc recently listed on the AIM Exchange in London under thesymbol AMP. Amphion's business is the formation, financing, management anddevelopment of life science and technology companies, working in partnershipwith corporations, governments, universities, and entrepreneurs seeking tocommercialize their intellectual property. On the Web: www.amphionplc.com About Motif BioSciences Motif BioSciences is a population genetics company focused on discovering genescausing common diseases by utilising human genetic data from the Persian/ArabianGulf region. Motif is headquartered in the US and London, with additionaloperations in the Gulf region to develop epidemiological, genealogical andgenetic information. On the Web: www.motifbio.com This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
23rd Jul 20127:00 amRNSDirectors Dealings
20th Jul 201212:00 pmRNSFunding Update
20th Jul 20127:00 amRNSTrading Statement
11th Jun 20127:00 amRNSFinal Results
9th May 20129:20 amRNSFunding update
1st May 20127:00 amRNSPartner Company Update
28th Mar 20127:00 amRNSPartner Company Update
28th Feb 20127:00 amRNSDirector Dealings
23rd Feb 20124:36 pmRNSFunding Update
3rd Feb 20123:24 pmRNSFunding Update
2nd Feb 20127:00 amRNSPatent Approval
30th Dec 20117:00 amRNSDirector Dealings
6th Dec 20119:09 amRNSDirector/PDMR Shareholding
21st Nov 20118:42 amRNSNew Suits Filed and New Debt Facilites
29th Sep 20117:00 amRNSHalf Yearly Report
21st Sep 20117:00 amRNSNotice of Results
9th Sep 20117:00 amRNSIssue of Equity
2nd Aug 20117:00 amRNSTrading Statement
28th Jul 20117:00 amRNSAdjournment of AGM
22nd Jul 20118:20 amRNSDirector/PDMR Shareholding
21st Jul 20119:03 amRNSDirector/PDMR Shareholding
30th Jun 20117:00 amRNSFinal Results
21st Jun 20114:44 pmRNSNew Debt Facility
24th May 20117:00 amRNSDisposal
15th Apr 20119:19 amRNSNew debt facility
14th Apr 20117:00 amRNSNotice of Results
13th Apr 20117:00 amRNSUpdate on Data Tern Patent Litigation
30th Mar 20117:00 amRNSIP Licences and Directorate Change
28th Feb 20117:00 amRNSTrading Statement
6th Jan 20117:00 amRNSChange of Adviser
5th Jan 20117:00 amRNSIP License Agreements
9th Dec 20107:00 amRNSNew Debt Facility
25th Oct 20107:00 amRNSPartner Update
18th Oct 20103:50 pmRNSDirector/PDMR Shareholding
30th Sep 20104:19 pmRNSTotal Voting Rights
24th Sep 20107:00 amRNSIP Licensing
22nd Sep 20108:00 amRNSGrant Win by Partner Company Firestar
10th Sep 20107:00 amRNSHalf Yearly Report
8th Sep 20107:00 amRNSIssue of Equity
2nd Aug 20102:54 pmRNSTotal Voting Rights
30th Jun 20107:00 amRNSIssue of Equity
29th Jun 20107:00 amRNSPartner Company Kromek acquires US Company
8th Jun 20107:00 amRNSAGM Statement
18th May 20107:00 amRNSDirector/PDMR Shareholding
30th Mar 20103:21 pmRNSDirector/PDMR Shareholding
16th Mar 20107:00 amRNSFinal Results
15th Mar 20107:00 amRNSPartner Company Kromek Completes Fundraising
8th Mar 20107:00 amRNSNotice of Results
2nd Feb 20107:00 amRNSTrading Update
6th Jan 20107:00 amRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.